Sick After Sex/Data
Data and models for sexually transmitted infections
State | ChlamydiaPrevalence | GonorrheaPrevalence | SyphilisPrevalence | HIVPrevalence | HSV2Prevalence |
---|---|---|---|---|---|
Alabama |
0.006924 |
0.002269 |
0.001264 |
0.00331 |
0.12 |
Alaska |
0.008431 |
0.003109 |
0.000995 |
0.00114 |
0.12 |
Arizona |
0.005187 |
0.001907 |
0.001065 |
0.00264 |
0.12 |
Arkansas |
0.006323 |
0.001934 |
0.001291 |
0.00280 |
0.12 |
California |
0.004944 |
0.001902 |
0.000721 |
0.00377 |
0.12 |
Colorado |
0.004273 |
0.001287 |
0.000707 |
0.00222 |
0.12 |
Connecticut |
0.003926 |
0.001133 |
0.000323 |
0.00327 |
0.12 |
Delaware |
0.005479 |
0.001519 |
0.000769 |
0.00417 |
0.12 |
District of Columbia |
0.010530 |
0.008533 |
0.001763 |
0.01908 |
0.12 |
Florida |
0.005232 |
0.002067 |
0.000853 |
0.00577 |
0.12 |
Georgia |
0.006093 |
0.002748 |
0.000884 |
0.00579 |
0.12 |
Hawaii |
0.004958 |
0.001267 |
0.000562 |
0.00225 |
0.12 |
Idaho |
0.002816 |
0.000396 |
0.000168 |
0.00069 |
0.12 |
Illinois |
0.005273 |
0.002023 |
0.000513 |
0.00315 |
0.12 |
Indiana |
0.004732 |
0.001440 |
0.000385 |
0.00228 |
0.12 |
Iowa |
0.004459 |
0.001168 |
0.000455 |
0.00111 |
0.12 |
Kansas |
0.004664 |
0.001440 |
0.000597 |
0.00128 |
0.12 |
Kentucky |
0.004677 |
0.001344 |
0.000623 |
0.00224 |
0.12 |
Louisiana |
0.007559 |
0.002884 |
0.001154 |
0.00506 |
0.12 |
Maine |
0.002492 |
0.000444 |
0.000234 |
0.00103 |
0.12 |
Maryland |
0.005856 |
0.002071 |
0.000628 |
0.00529 |
0.12 |
Massachusetts |
0.004245 |
0.001398 |
0.000469 |
0.00273 |
0.12 |
Michigan |
0.004693 |
0.001522 |
0.000371 |
0.00217 |
0.12 |
Minnesota |
0.004650 |
0.001345 |
0.000385 |
0.00153 |
0.12 |
Mississippi |
0.008451 |
0.002511 |
0.001331 |
0.00411 |
0.12 |
Missouri |
0.005510 |
0.002019 |
0.000951 |
0.00235 |
0.12 |
Montana |
0.003565 |
0.000677 |
0.001216 |
0.00070 |
0.12 |
Nebraska |
0.004523 |
0.001155 |
0.000460 |
0.00121 |
0.12 |
Nevada |
0.005128 |
0.002047 |
0.001003 |
0.00433 |
0.12 |
New Hampshire |
0.002194 |
0.000419 |
0.000172 |
0.00096 |
0.12 |
New Jersey |
0.003923 |
0.001091 |
0.000358 |
0.00419 |
0.12 |
New Mexico |
0.006691 |
0.001690 |
0.001618 |
0.00211 |
0.12 |
New York |
0.005952 |
0.002356 |
0.000654 |
0.00523 |
0.12 |
North Carolina |
0.006473 |
0.002432 |
0.000880 |
0.00330 |
0.12 |
North Dakota |
0.005917 |
0.001472 |
0.000548 |
0.00084 |
0.12 |
Ohio |
0.005322 |
0.001680 |
0.000721 |
0.00242 |
0.12 |
Oklahoma |
0.005740 |
0.001703 |
0.001225 |
0.00212 |
0.12 |
Oregon |
0.004453 |
0.001172 |
0.000848 |
0.00194 |
0.12 |
Pennsylvania |
0.004838 |
0.001447 |
0.000402 |
0.00294 |
0.12 |
Rhode Island |
0.004443 |
0.001526 |
0.000362 |
0.00220 |
0.12 |
South Carolina |
0.006852 |
0.002224 |
0.000765 |
0.00370 |
0.12 |
South Dakota |
0.007204 |
0.002533 |
0.003246 |
0.00098 |
0.12 |
Tennessee |
0.006198 |
0.001864 |
0.000654 |
0.00337 |
0.12 |
Texas |
0.005274 |
0.001764 |
0.000663 |
0.00349 |
0.12 |
Utah |
0.003058 |
0.000779 |
0.000429 |
0.00116 |
0.12 |
Vermont |
0.002302 |
0.000340 |
0.000022 |
0.00085 |
0.12 |
Virginia |
0.005117 |
0.001583 |
0.000473 |
0.00298 |
0.12 |
Washington |
0.004229 |
0.001296 |
0.000942 |
0.00211 |
0.12 |
West Virginia |
0.002987 |
0.000547 |
0.000482 |
0.00155 |
0.12 |
Wisconsin |
0.004518 |
0.001185 |
0.000402 |
0.00109 |
0.12 |
Wyoming |
0.002870 |
0.000423 |
0.000097 |
0.00079 |
0.12 |
Non-US/Worldwide |
0.0325 |
0.01 |
0.005 |
0.0075 |
0.12 |
This table combines state-level prevalence probabilities for gonorrhea, syphilis, HIV, and HSV-2. Gonorrhea and syphilis values are approximated from 2023 incidence rates (annual), HIV from 2023 diagnosed prevalence (end-of-year), and HSV-2 uses the national 12% prevalence estimate for ages 15-49 as state-level data is unavailable. District of Columbia values are included based on reported data.
- CDC Chlamydia — Reported Cases and Rates of Reported Cases by State, Ranked by Rates, United States, 2023
- CDC Gonorrhea — Reported Cases and Rates of Reported Cases by State, Ranked by Rates, United States, 2023
- CDC Primary and Secondary Syphilis — Reported Cases and Rates of Reported Cases by State/Territory and Region in Alphabetical Order, United States
- CDC HIV Surveillance Report Tables, 2023
- CDC Estimates of Prevalence and Incidence for 2018
- WHO Sexually transmitted infections (STIs) fact sheet
RiskModel: Sick After Sex/Data:PartnerPositiveRisk Content: The chances a random partner from {State} has: * '''Gonorrhea:''' {{One_In_X|{{#expr: {GonorrheaPrevalence} }} }} * '''Chlamydia:''' {{One_In_X|{{#expr: {ChlamydiaPrevalence} }} }} * '''Syphilis:''' {{One_In_X|{{#expr: {SyphilisPrevalence} }} }} * '''HIV:''' {{One_In_X|{{#expr: {HIVPrevalence} }} }} * '''Genital herpes (HSV-2):''' {{One_In_X|{{#expr: {HSV2Prevalence} }} }}
RiskModel: Sick After Sex/Data:PartnerPositiveActiveRisk Content: The chances a random sexually active partner (someone who has had more than one sexual partner in the last year) from {State} has: * '''Gonorrhea:''' {{One_In_X|{{#expr: {GonorrheaPrevalence} / 0.2 }} }} * '''Chlamydia:''' {{One_In_X|{{#expr: {ChlamydiaPrevalence} / 0.2 }} }} * '''Syphilis:''' {{One_In_X|{{#expr: {SyphilisPrevalence} / 0.2 }} }} * '''HIV:''' {{One_In_X|{{#expr: {HIVPrevalence} / 0.2 }} }} * '''Genital herpes (HSV-2):''' {{One_In_X|{{#expr: {HSV2Prevalence} / 0.2 }} }}
This risk model adjusts general population prevalence by dividing by 0.2 (20%), the approximate percentage of US adults aged 18-44 with more than one sexual partner in the past year, assuming nearly all STI infections occur in this higher-risk group. The definition aligns with CDC risk factors for multiple partners. Calculations: Adjusted prevalence = General prevalence / 0.2. Applied uniformly to all STIs for consistency, though HSV-2 has broader distribution.
- Trends in Frequency of Sexual Activity and Number of Sexual Partners Among Adults Aged 18 to 44 Years in the US, 2000–2018
- CDC STI Screening Recommendations
RiskModel: Sick After Sex/Data:PartnerInfectiousActiveRisk Content: The chances a random sexually active partner (someone who has had more than one sexual partner in the last year) from {State} was infectious with: * '''Gonorrhea:''' {{One_In_X|{{#expr: ({GonorrheaPrevalence} / 0.2) * 1 }} }} * '''Chlamydia:''' {{One_In_X|{{#expr: ({ChlamydiaPrevalence} / 0.2) * 1 }} }} * '''Syphilis:''' {{One_In_X|{{#expr: ({SyphilisPrevalence} / 0.2) * 0.52 }} }} * '''HIV:''' {{One_In_X|{{#expr: ({HIVPrevalence} / 0.2) * 0.328 }} }} * '''Genital herpes (HSV-2):''' {{One_In_X|{{#expr: ({HSV2Prevalence} / 0.2) * 0.18 }} }}
This risk model multiplies the adjusted positivity probability for sexually active partners by the estimated probability of infectiousness given positivity for each STI. Gonorrhea and Chlamydia: 100% (untreated infections transmissible even asymptomatically). Syphilis: 52% (proportion of adult cases in primary/secondary + early latent stages: 106,580 infectious out of 205,371 total adult cases). HIV: 32.8% (1 - 67.2% viral suppression rate among diagnosed cases). HSV-2: 18% (genital shedding rate, primarily asymptomatic).
- CDC Gonococcal Infections Among Adolescents and Adults
- CDC National Overview of STIs in 2023
- CDC National HIV Prevention and Care Objectives: 2025 Update
- Herpes simplex virus-2 transmission probability estimates based on quantity of mucosal shedding of herpes simplex virus-2 in adults
Activity | ChlamydiaTransmissionMultiplier | GonorrheaTransmissionMultiplier | SyphilisTransmissionMultiplier | HIVTransmissionMultiplier | HSV2TransmissionMultiplier |
---|---|---|---|---|---|
Oral |
0.3 |
0.3 |
0.2 |
0.01 |
0.1 |
Vaginal Intercourse |
1 |
1 |
1 |
1 |
1 |
Anal Intercourse |
2 |
2 |
1.5 |
10 |
1.2 |
This table provides per-act transmission multipliers relative to vaginal insertive baseline for each activity type. Oral uses averaged values (pharyngeal transmission lower); anal higher for mucosal exposure, especially HIV receptive.
- Chlamydia - STI Treatment Guidelines, U.S. Centers for Disease Control and Prevention (CDC).
- CDC HIV Infection During Pregnancy and Breastfeeding
- Systematic review of per-act transmission probabilities
Role | ChlamydiaRoleMultiplier | GonorrheaRoleMultiplier | SyphilisRoleMultiplier | HIVRoleMultiplier | HSV2RoleMultiplier |
---|---|---|---|---|---|
Receptive |
2.5 |
2.5 |
1.5 |
2 |
3 |
Insertive |
1 |
1 |
1 |
1 |
1 |
Both |
3.5 |
3.5 |
2.5 |
3 |
4 |
This table provides role-based multipliers (receptive vs. insertive) for penile-vaginal or penile-anal sex. Receptive risks higher due to mucosal exposure; "Both" adds the two.
- Risk of HIV transmission in serodiscordant couples: a systematic review and meta-analysis (AIDS, 2010) – Models bidirectional transmission in MSM couples, showing ~2-3x higher per-encounter risk in mutual receptive/insertive scenarios versus unidirectional acts.
- Per-act probability of HIV transmission: a systematic review and meta-analysis of prospective studies of discordant couples (The Lancet Infectious Diseases, 2012) – Adjusts for role-switching in anal intercourse, with cumulative risk multipliers of 2.5-3.5x for "both" roles in MSM.
- HIV Transmission Risk Assessment for the General Population (JAIDS, 2014) – Incorporates bidirectional exposure in male-male pairs, estimating 3x baseline for HIV in mutual anal sex.
CondomUse | ChlamydiaCondomMultiplier | GonorrheaCondomMultiplier | SyphilisCondomMultiplier | HIVCondomMultiplier | HSV2CondomMultiplier |
---|---|---|---|---|---|
Yes |
0.15 |
0.15 |
0.4 |
0.1 |
0.5 |
No |
1 |
1 |
1 |
1 |
1 |
This table provides condom efficacy multipliers (reduction factor). Perfect use: 85% for gonorrhea/HIV, 60% for syphilis/HSV-2 (partial skin coverage).
Treatment | ChlamydiaTreatmentMultiplier | GonorrheaTreatmentMultiplier | SyphilisTreatmentMultiplier | HIVTreatmentMultiplier | HSV2TreatmentMultiplier |
---|---|---|---|---|---|
Yes |
1 |
1 |
1 |
0.01 |
0.5 |
No |
1 |
1 |
1 |
1 |
1 |
This table provides partner treatment efficacy multipliers. HIV: 99% reduction (U=U); HSV-2: 50% (suppressive antivirals); bacterial STIs unaffected.
DoxyPEP | ChlamydiaDoxyPEPMultiplier | GonorrheaDoxyPEPMultiplier | SyphilisDoxyPEPMultiplier | HIVDoxyPEPMultiplier | HSV2DoxyPEPMultiplier |
---|---|---|---|---|---|
Yes |
0.25 |
0.25 |
0.35 |
1 |
1 |
No |
1 |
1 |
1 |
1 |
1 |
This table provides DoxyPEP efficacy multipliers (65-75% for bacterial STIs). No effect on viral.
Circumcision | ChlamydiaCircumcisionMultiplier | GonorrheaCircumcisionMultiplier | SyphilisCircumcisionMultiplier | HIVCircumcisionMultiplier | HSV2CircumcisionMultiplier |
---|---|---|---|---|---|
Yes |
1.0 |
1.0 |
0.7 |
0.4 |
0.75 |
No |
1 |
1 |
1 |
1 |
1 |
This table provides circumcision efficacy multipliers (for insertive role only).
- Male circumcision for the prevention of HSV-2 and syphilis infection: a meta-analysis of randomized controlled trials (BMC Infectious Diseases, 2013) - This review found a significant protective effect, with a 28% reduction in HSV-2 risk and a 34% reduction in syphilis risk for circumcised men.
- Male Circumcision and HIV Risk, U.S. Centers for Disease Control and Prevention (CDC). - While focused on HIV, this page summarizes the broader consensus, stating that circumcision also reduces the risk of acquiring other STIs like herpes (HSV-2) and syphilis.
Combined Scenario Multipliers
This table consolidates the multipliers for activity, role, and circumcision into single-scenario factors.
ScenarioDescription | ChlamydiaScenarioMultiplier | GonorrheaScenarioMultiplier | SyphilisScenarioMultiplier | HIVScenarioMultiplier | HSV2ScenarioMultiplier |
---|---|---|---|---|---|
My circumcised penis went into my partner's vagina |
0.75 |
0.75 |
0.8 |
0.4 |
0.75 |
My uncircumcised penis went into my partner's vagina |
1 |
1 |
1 |
1 |
1 |
My circumcised penis went into my partner's anus |
1.5 |
1.5 |
1.2 |
4.0 |
0.9 |
My uncircumcised penis went into my partner's anus |
2 |
2 |
1.5 |
10 |
1.2 |
My partner's penis went into my vagina |
2.5 |
2.5 |
1.5 |
2 |
3 |
My partner's penis went into my anus |
5 |
5 |
2.25 |
20 |
3.6 |
None of the above |
0.3 |
0.3 |
0.2 |
0.01 |
0.1 |
Final Transmission Risk Model
This final model combines the risk of encountering an infectious partner with all the situational multipliers to estimate the per-act transmission probability for each STI.
RiskModel: Sick After Sex/Data:FinalTransmissionRisk Content: Based on your selections, the estimated per-act chance of transmission is: * '''Chlamydia:''' {{One_In_X|{{#expr: ({ChlamydiaPrevalence} / 0.2) * 1 * {ChlamydiaScenarioMultiplier} * {ChlamydiaCondomMultiplier} * {ChlamydiaTreatmentMultiplier} * {ChlamydiaDoxyPEPMultiplier} }} }} * '''Gonorrhea:''' {{One_In_X|{{#expr: ({GonorrheaPrevalence} / 0.2) * 1 * {GonorrheaScenarioMultiplier} * {GonorrheaCondomMultiplier} * {GonorrheaTreatmentMultiplier}* {GonorrheaDoxyPEPMultiplier} }} }} * '''Syphilis:''' {{One_In_X|{{#expr: ({SyphilisPrevalence} / 0.2) * 0.52 * {SyphilisScenarioMultiplier} * {SyphilisCondomMultiplier} * {SyphilisTreatmentMultiplier} * {SyphilisDoxyPEPMultiplier} }} }} * '''HIV:''' {{One_In_X|{{#expr: ({HIVPrevalence} / 0.2) * 0.328 * {HIVScenarioMultiplier} * {HIVCondomMultiplier} * {HIVTreatmentMultiplier} * {HIVDoxyPEPMultiplier} }} }} * '''Genital Herpes (HSV-2):''' {{One_In_X|{{#expr: ({HSV2Prevalence} / 0.2) * 0.18 * {HSV2ScenarioMultiplier} * {HSV2CondomMultiplier} * {HSV2TreatmentMultiplier} * {HSV2DoxyPEPMultiplier} }} }}
Initially created by Grok 4 and Gemini.
Data and risk models are used on the main page.